Viimeisimmät artikkelit
- Phase 2 trial for birch pollen allergy treatment DM-101PX approved by Health Canada
- Kutsu Desentum Oy:n varsinaiseen yhtiökokoukseen / Summons to Annual General Meeting of Desentum Oy
- Desentum to present clinical results of investigational birch pollen allergy vaccine DM-101PX and scientific discoveries about peanut allergy at the world’s largest allergy congress
- Desentum reports strong safety and immunological data from Phase 1 clinical study with investigational birch pollen allergy vaccine DM-101PX
- Ilmoitus osakkeiden siirtymisestä Desentum Oy:n osakkeenomistajille
Viimeisimmät kommentit
No comments to show.